Editor: Antti Jekunen

The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo

eBook: US $89 Special Offer (PDF + Printed Copy): US $151
Printed Copy: US $107
Library License: US $356
ISBN: 978-1-68108-866-2 (Print)
ISBN: 978-1-68108-865-5 (Online)
Year of Publication: 2022
DOI: 10.2174/97816810886551220101


The Evolution of Radionanotargeting towards Clinical Precision Oncology is a remarkable book honoring Professor Kalevi Kairemo, who is known among academic and medical circles as a pioneer in novel radiolabeled therapeutics. This festschrift provides an overview of key advances in the field of radionanotargeting, and the directions for future development in patient care. Prof Kairemo’s research is based on multiomics, which involves multiple elements: genomics, transcriptomics, proteomics, metabolomics, microbiomics, epigenomics, exposome, imaging, and precision medicine, which is reflected by the unique collection of articles presented. The articles start from the angle of radionanotargeting and theragnostics leading to imaging and therapy, which includes sections for thyroid cancer, head and neck cancer, genitourinary cancers and neuroendocrine neoplasms. Theragnostics, nanoparticles and precision oncology have also been covered in their own segments, while also giving a glimpse of research in metabolic imaging, cardiovascular radionuclide imaging, and bone therapies. The sequence of chapters demonstrates how, through Professor Kairemo’s efforts, radionanotargeting has evolved to a practice changing therapeutic approach in the clinic, particularly in oncology. Finally, Professor Kairemo’s own memoir, “Seven decades in health care” and memoirs from colleagues including a personal introduction to him with a photographic cavalcade reveals the world of a multitasking person with a multidisciplinary approach to science, that ushered his development of significant expertise across the fields of chemistry, biology, engineering, physics and clinical medicine. This book is excellent for medical historians, trainees and specialists in clinical and radiological oncology in expanding their understanding of the role of radionuclide imaging over the years, making it an ideal tribute that belongs in the library of anyone involved in the field.


The last decade has seen the emergence of radionanotargeting as a practice changing therapeutic approach in the clinic, particularly in the field of oncology. This has extended from regulatory approvals for radiolabeled peptide therapy in somatostatin-expressing tumors (1), to impressive results with radiolabeled peptides and antibodies against prostate-specific membrane antigen (PSMA) in prostate cancer patients (2), and exciting results for a broad array of radiolabeled engineered protein and peptide-based therapeutics and nanoparticles extending from preclinical studies into human trials (3-5). The breadth of clinical activity across countries and in different clinical areas clearly demonstrates the momentum for the field.

The ability of molecular imaging with radiotracers to identify targets suitable for therapy in individual patients was established decades ago with 131I as an exemplar of precision oncology, and which now extends to an impressive array of cellular, microenvironment and immune targets which can be used for therapeutic approaches (3,4). The principles of therapeutic drug development utilizing an initial imaging based approach, which eliminates the potential for error of biopsy results for assessment of genomic or protein expression profiles in tumors, has been built on painstaking validation and pioneering work over many years (5-7). The development of novel targeting and radiochemistry approaches, protein design, preclinical validation, and extension into carefully conducted human trials, has provided the basis for the current approach to treating patients utilizing targeting molecules and an image-guided, or "theranostics" approach.

In addition to the developments in targeting techniques, imaging and therapeutic radionuclide approaches, the technology developed in this field has also led to new ways to improve drug development. Through sophisticated radioimaging studies, new drugs can be assessed for biodistribution, pharmacokinetics and pharmacodynamics, which can dramatically impact patient and dose selection, and clinical development programs (6,7). This approach is being increasingly used by pharmaceutical companies and biotech as they develop new therapeutics.

"The Evolution of Radionanotargeting towards Clinical Precision Oncology" provides an overview of key advances in the field of radionanotargeting, and the directions in which this area of medicine will have an impact on patient care. Our colleague, Prof Kalevi Kareimo, has been a pioneer in this field through his research and clinical translation of novel radiolabeled therapeutics. This has required his pursuing a ground-breaking multidisciplinary approach to science, development of significant expertise across the fields of chemistry, biology, engineering, physics and clinical medicine, and the ability to assemble teams for a common scientific purpose. We have enjoyed the collaboration, scientific endeavour, and friendship of Kalevi for almost 30 years, beginning with our time spent working together at Memorial Sloan-Kettering Cancer Centre, and we can attest to his insight, determination, and commitment to the field and patient care throughout this time (Figure 1). This Festschrift book provides a wonderful outline of the field and his achievements over many years.


1. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med 376(2):125-135, 2017.

2. Hofman MS, Emmett L, Sandhu S, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 397(10276):797-804, 2021.

3. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 12(4):278-87, 2012.

4. Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med 60(6):801-805, 2019.

5. Larson SM, Carrasquillo JA, Cheung NK, Press OW. Radioimmunotherapy of human tumours. Nat Rev Cancer 15(6):347-60, 2015.

6. Ciprotti M, Tebbutt NC, Lee FT, et al. A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients with Metastatic Colorectal Cancer. J Clin Oncol 33(24):2609-2616, 2015.

7. Pillarsetty N, Jhaveri K, Taldone T, et al. Paradigms for Precision Medicine in Epichaperome Cancer Therapy. Cancer Cell 36(5):559-573.e7, 2019.

Figure 1. 14th International Symposium on Radiopharmaceutical Therapy (WARMTH), Helsinki City Hall, November 2018: Homer Macapinlac, Steven Larson, Kalevi Kairemo, Andrew Scott

Andrew M. Scott
Department of Molecular Imaging and Therapy
Austin Health, and University of Melbourne
Olivia Newton-John Cancer Research Institute and School of Cancer Medicine,
La Trobe University

Homer A. Macapinlac
Department of Nuclear Medicine
MD Anderson Cancer Center
Houston, Texas


Steven M. Larson
Molecular Imaging and Therapy Service
Memorial Sloan-Kettering Cancer Centre
New York, NY


.Alternative Remedies and Natural Products for Cancer Therapy: An Integrative Approach.
.The Management of Metastatic Triple-Negative Breast Cancer: An Integrated and Expeditionary Approach.
.Cancer Medicine in an Ayurvedic Perspective: A Critical Overview.